UA101057C2 - Pyrimidine derivatives as kinase inhibitors - Google Patents

Pyrimidine derivatives as kinase inhibitors

Info

Publication number
UA101057C2
UA101057C2 UAA201104068A UAA201104068A UA101057C2 UA 101057 C2 UA101057 C2 UA 101057C2 UA A201104068 A UAA201104068 A UA A201104068A UA A201104068 A UAA201104068 A UA A201104068A UA 101057 C2 UA101057 C2 UA 101057C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine derivatives
kinase inhibitors
analplastic
igf
alk
Prior art date
Application number
UAA201104068A
Other languages
English (en)
Ukrainian (uk)
Inventor
ИИИ Томас Х. Марсилье
Уэншуо Лу
Бей Чен
Ксяогуй Хи
Кристиан Чо-Хуа Ли
Сонгчун Джианг
Кунйонг Янг
Original Assignee
Айерем Элелси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айерем Элелси filed Critical Айерем Элелси
Priority claimed from PCT/US2009/048428 external-priority patent/WO2010002655A2/en
Publication of UA101057C2 publication Critical patent/UA101057C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение обеспечивает новые производные пиримидина, их фармацевтические композиции и применение таких соединений.Например, производные пиримидина данного изобретения могут быть использованы для лечения, облегчения симптомов или профилактики состояния, реагирующего на ингибирование инсулиноподобного фактора роста (IGF-1R) или киназы анапластической лимфомы (ALK).
UAA201104068A 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors UA101057C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048428 WO2010002655A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
UA101057C2 true UA101057C2 (en) 2013-02-25

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201104068A UA101057C2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors

Country Status (11)

Country Link
EP (1) EP2331526A2 (ru)
JP (1) JP2011526291A (ru)
KR (1) KR20110020940A (ru)
CN (1) CN102203083A (ru)
AU (1) AU2009262198B2 (ru)
BR (1) BRPI0914545A2 (ru)
CA (1) CA2729546A1 (ru)
EA (1) EA201100078A1 (ru)
MX (1) MX2010014568A (ru)
UA (1) UA101057C2 (ru)
WO (1) WO2009158431A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
EP2917210B1 (en) 2012-11-06 2019-02-27 Shanghai Fochon Pharmaceutical Co. Ltd Alk kinase inhibitors
JP6433974B2 (ja) * 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
JP6339241B2 (ja) * 2014-05-30 2018-06-06 ベイジン・パール・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー Ａｌｋキナーゼ阻害剤並びにその調製方法及び使用
CN110312711A (zh) * 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
CN107488148A (zh) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 一种苯丙酰胺类杀虫剂及其制备方法
IL275490B2 (en) 2017-12-22 2024-05-01 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
NZ545270A (en) * 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1663242B1 (en) * 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
CA2656290A1 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
ES2559528T3 (es) * 2006-12-08 2016-02-12 Novartis Ag Compuestos y composiciones como inhibidores de proteína cinasa
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂

Also Published As

Publication number Publication date
CN102203083A (zh) 2011-09-28
EP2331526A2 (en) 2011-06-15
MX2010014568A (es) 2011-03-29
WO2009158431A2 (en) 2009-12-30
JP2011526291A (ja) 2011-10-06
AU2009262198A1 (en) 2009-12-30
EA201100078A1 (ru) 2011-08-30
KR20110020940A (ko) 2011-03-03
CA2729546A1 (en) 2009-12-30
BRPI0914545A2 (pt) 2017-05-23
WO2009158431A3 (en) 2010-03-11
AU2009262198B2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
UA101057C2 (en) Pyrimidine derivatives as kinase inhibitors
UA100846C2 (ru) Соединения и композиция как ингибиторы протеинкиназы
TN2009000225A1 (en) Compounds and compositions as protein kinase kinase inhibitors
MX2010010968A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
WO2009126514A8 (en) Compounds and compositions as kinase inhibitors
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2009000884A (es) Derivados de piridizinona.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MX2009003793A (es) Inhibidores de cinasa.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors